Effect of monthly ibandronate on hip structural geometry in men with low bone density

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 257-265

  Genant, H K ^a,b   Lewiecki, E M ^c   Fuerst, T ^b   Fries, M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SYNARC INC   (United States)

^c NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bone quality; Hip structural analysis; Ibandronate; Osteoporosis

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE STRUCTURE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMUR; FEMUR NECK; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 84857374514     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1732-9     Document Type: Article

References (38)

1. Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67:1521-1526 (Pubitemid 36427944)
2. National Osteoporosis Foundation (2008) Fast facts on osteoporosis. Web site of the National Osteoporosis Foundation. http://www.nof.org/osteoporosis/ diseasefacts.htm#top. Accessed September 8, 2009
3. Fransen M, Woodward M, Norton R, Robinson E, Butler M, Campbell AJ (2002) Excess mortality or institutionalization after hip fracture: men are at greater risk than women. J Am Geriatr Soc 50:685-690 (Pubitemid 34298756)
4. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203-209
5. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970-976
6. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550-1556 (Pubitemid 44484599)
7. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194 (Pubitemid 40863806)
8. Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4:50-63 (Pubitemid 38714795)
9. Wachter NJ, Augat P, Krischak GD, Sarkar MR, Mentzel M, Kinzl L, Claes L (2001) Prediction of strength of cortical bone in vitro by microcomputed tomography. Clin Biomech Bristol Avon 16:252-256 (Pubitemid 32178313)
10. Wachter NJ, Krischak GD, Mentzel M, Sarkar MR, Ebinger T, Kinzl L, Claes L, Augat P (2002) Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone 31:90-95 (Pubitemid 34754431)
11. Silverman SL, Cummings SR, Watts NB (2008) Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 23:159-165
12. Bonnick SL (2007) HSA: beyond BMD withDXA. Bone 41:S9-S12
13. Rubin CD (2005) Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21:1049-1056 (Pubitemid 41032694)
14. Pulkkinen P, Partanen J, Jalovaara P, Jamsa T (2004) Combination of bone mineral density and upper femur geometry improves the prediction of hip fracture. Osteoporos Int 15:274-280 (Pubitemid 38543945)
15. Bouxsein ML (2004) Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact 4:404-405 (Pubitemid 40124881)
16. Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA (2009) Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 94:171-180
17. Beck TJ, Looker AC, Ruff CB, Sievanen H, Wahner HW (2000) Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15:2297-2304
18. Epstein S (2007) Is cortical bone hip? What determines cortical bone properties? Bone 41:S3-S8 (Pubitemid 46921511)
19. Russo CR, Lauretani F, Seeman E, Bartali B, Bandinelli S, Di Iorio A, Guralnik J, Ferrucci L (2006) Structural adaptations to bone loss in aging men and women. Bone 38:112-118 (Pubitemid 43006081)
20. Orwoll ES, Klein RF (1995) Osteoporosis in men. Endocr Rev 16:87-116
21. Fuerst T, Beck TJ, Gaither K, Kothari M, Genant HK (2006) Effect of oral ibandronate on hip structure: results from the BONE study (abstract). J Bone Miner Res 21:S287
22. Beck T (2003) Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 14(Suppl 5):S81-S88
23. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE (2009) DXA-based hip structural analysis of onceweekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911-921
24. Prevrhal S, Shepherd JA, Faulkner KG, Gaither KW, Black DM, Lang TF (2008) Comparison of DXA hip structural analysis with volumetric QCT. J Clin Densitom 11:232-236
25. Beck T (2002) Hip structural analysis (HSA) program (BMD and structural geometry methodology) as used to create NHANES III dataset. CDC electronic file. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Datasets/NHANES/NHANESIII/17a/hip- methods.pdf. Accessed February 18, 2010
26. Melton LJ 3rd, Beck TJ, Amin S, Khosla S, Achenbach SJ, Oberg AL, Riggs BL (2005) Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 16:460-467
27. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 20:1525-1532 (Pubitemid 41243541)
28. Beck TJ, Cauley JA, de Papp AE, Wehren LE, Baran DT (2006) Alendronate improves the structural geometry of the proximal femur in postmenopausal osteoporotic women (abstract). Osteoporos Int 17:S73
29. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Baran D, Shah A, Wang H, Wehren LE, de Papp AE (2006) Comparison of effects of alendronate versus risedronate on the structural geometry of the hip: an analysis of the US Fosamax Actonel Comparison Trial (FACT) extension data (abstract). J Bone Miner Res 21:S180
30. van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL (2008) Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone 43:274-278
31. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575-586
32. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510-516
33. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez- Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17 (Pubitemid 36008334)
34. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948-958 (Pubitemid 40797995)
35. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351-359
36. Yates LB, Karasik D, Beck TJ, Cupples LA, Kiel DP (2007) Hip structural geometry in old and old-old age: similarities and differences between men and women. Bone 41:722-732 (Pubitemid 47393665)
37. Kaptoge S, Dalzell N, Loveridge N, Beck TJ, Khaw KT, Reeve J (2003) Effects of gender, anthropometric variables, and aging on the evolution of hip strength in men and women aged over 65. Bone 32:561-570 (Pubitemid 39665716)
38. Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5:49-55 (Pubitemid 46954741)